Search results for: Health Policy and Regulation
Filter search results
OHE Models Incentives for Antibiotic Drug Development
18 March 2014
The OHE model takes into account the value to society of new antibiotics as well as the risks and rewards for payers and the entities developing the new drugs. A…
A Framework for Payer Assessment of the Value of New Technologies: A US Approach
10 March 2015
…is a Lecturer in the Department of Population Medicine at Harvard Medical School and has served as Special Advisor, Technology and Coverage Policy, within the Coverage and Analysis Group at…
OHE Publishes in the Journal of Comparative Effectiveness Research: Future Expectations of Evidence of Relative Effectiveness in Europe and Comparative Effectiveness in the USA in 2020
15 April 2015
…Technology Policy (CMTP) and Penny Mohr of the Patient-Centered Outcomes Research Institute (PCORI). Patients and those paying for healthcare increasingly want evidence of the additional benefit one treatment offers…
Recently Published: Payer Perspectives on Future Acceptability of Comparative Effectiveness and Relative Effectiveness Research
18 August 2015
…companies: Amgen, GSK, Lilly, Novartis and Sanofi. The study included interviews with and a survey of ‘key informants’ (senior officials representing public and private payers, HTA bodies and Government…
Bhaven N. Sampat
20 January 2023
Bhaven N. Sampat is an economist by training, a Professor at the Department of Health Policy and Management at Columbia University, and a Research Associate at the National Bureau of…
Care at the End of Life: An Economic Perspective
6 April 2016
…of life is an increasing concern amongst policy makers and providers of health and social care. Just published is a book on the methodological, policy and ethical challenges facing economists…
Enhancing the Benefits from Biomedical and Health Research Spillovers
1 October 2010
…UK science and technology policy. This OHE Occasional Paper discusses key aspects of spillovers and identifies top priorities for policy research that could help bring spillover effects more explicitly into…
A Framework for Payer Assessment of the Value of New Technologies: A US Approach
1 March 2015
Dr Steven Pearson has convened a US policy workgroup of payers, drug and device manufacturers, patients’ groups, and clinician specialty societies to help develop a “value framework”. Dr Steven Pearson…
Variations between General Practitioners
1 July 1990
…prescriptions for medicines are considered. And third, current policy responses towards these variations are discussed briefly with an assessment of their likely impact upon the cost and quality of care….